drugset
Drugs / MVA-MERS-S
last change Jul 2022 re-read 3 minutes ago

MVA-MERS-S

Vaccine

Developed for
Middle East respiratory syndrome
Investigated by
Bernhard Nocht Institute for Tropical Medicine · Charite University, Berlin, Germany · Ludwig-Maximilians - University of Munich · Marylyn Addo · Philipps University Marburg · University of Cologne

Trials 1

today NCT03615911 · Ph 1
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03615911 Nov 2017 → Apr 2019 Middle East respiratory syndrome Marylyn Addo Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as MVA-MERS-S ClinicalTrials.gov intervention name — accepted as the source's own label NCT03615911 ↗
Modality Vaccine “modified vaccinia virus Ankara (MVA)-based vaccine MVA-MERS-S” PMID 35858586 ↗ Jul 2022
Route Intramuscular “MVA-MERS-S intramuscularly” PMID 32325037 ↗ Apr 2020